DiscoverSolutions OP Clinical Trials UK
Solutions OP Clinical Trials UK
Claim Ownership

Solutions OP Clinical Trials UK

Author: Olga Peycheva

Subscribed: 5Played: 50
Share

Description

This podcast is dedicated to clinical trials and clinical research. We will be discussing different hot topics and analysis of the latest developments in clinical trials in pharmaceutical and medical devices industries. We have interviews with different industry experts.

New episodes will be available every 2 weeks.

44 Episodes
Reverse
In this episode you can learn about the challenges of conducting clinical trials in Africa but also about some ongoing work which is aiming to create more opportunities for clinical research on the continent. In addition, there are some practical recommendations what could help African countries to establish better clinical research facilities and network.
There is a growing call for more wide-spread prostate cancer screening. In this episode you can learn about the methods used for prostate screening and some promising new research in the field. It will also answer the question why the medical bodies are against the roll out of the screening program to more men.
The guest of this episode is Liz Hawes who is a registered nurse specialising in wound care and also CEO of a company providing clinical research services. She provides an overview on the current situation with wound care and the available treatment options. We also discuss what could be done to improve wound healing and attract clinical research in the field. In addition, she gave very powerful examples of the critical importance of wound healing and how it can have a significant impact on patients' lives.You can read the script here: https://solutionsop.co.uk/2025/12/26/how-important-is-wound-healing-interview-with-liz-hawes/
This episode is analysis of the effect of Assisted Dying Bill in the UK on clinical research. It examines why it patients with advanced diseases are critical for developing new drugs. It also explores if we should offer patients option to participate in clinical research instead of assisted dying.Why should we offer patients opportunity to participate in clinical research instead of assisted dying option? You can find out in this episode.
This episode is a quick recap of the Regulatory Intelligence Conference which happened on 3rd and 4th of Nov 2025 in London. The event was organised by TOPRA and RAPS. It also contains analysis on how startups companies are affected by lack of regulatory intelligence resources and what could be done to help startup companies to improve their access to regulatory intelligence.
In this episode of the podcast we are discussing patients engagement in clinical trial with Keith Berelowitz, who is the chair of Fulham Ethics Committee and entrepreneur working on a new AI powered platform aiming to improve recruitment in clinical trials. Apart from discussing how their platform pRxEngage operates we are also talking about the main challenges in recruiting patients in clinical trials and what could be done to improve reach out to different communities.You can read the transcript of our interview here: https://solutionsop.co.uk/2025/11/14/how-to-engage-more-patients-in-clinical-trials-interview-with-keith-berelowitz/
In this episode we are talking to Steven Edmunds, who is advanced nurse practitioner at Royal Marsden Hospital in London, UK. The focus of our discussion is the role of the nurse practitioners in clinical research but also as a career opportunity for experienced and knowledgeable research nurses looking to take on more responsibilities.You will be able to read the transcript of our discussion here: https://solutionsop.co.uk/2025/10/31/the-role-of-nurse-practitioners-in-clinical-research-interview-with-steven-edmunds/
This episode covers the latest developments in the UK life science sector where some big pharma companies are pausing investment or cancelling their investment projects. The analysis touches on the international situation and country specific problems which led to these consequences.
This episode is an overview of the FDA Chemistry Manufacturing Controls Pilot Program and lessons learnt from the current participants in the pilot. It covers what is the scope of the pilot program and some of the unique challenges in manufacturing. Would that pilot be useful for small pharma companies and startups?You can read our transcript here: https://solutionsop.co.uk/2025/10/09/is-the-fda-chemistry-manufacturing-controls-pilot-program-helpful-for-pharma-startups/
In this episode we are discussing the current challenges in the clinical research job market with the experienced recruiter, Harry Henson. He shares with us his advices for young job seekers who are looking to find their first job in clinical research after graduating school or university.Transcript of this interview is available here: https://solutionsop.co.uk/2025/10/01/finding-your-first-job-in-clinical-research-discussion-with-harry-henson/
In this episode, we discuss with our Senior Clinical Data Quality Manager, Lydia Ainsworth, our recent publication "Enhancing Informed Consent Forms for Medical Devices: International Regulatory Guidance and Ethical Recommendations"You can also find our publication translated in Chinese here: Translated version in ChineseIn our discussion we cover why we wrote this review, who the target audience is and how it could help medical devices manufacturers improve their informed consent forms (ICFs). We also talk about some ethical aspects and the checklists that we created as part of our review. It is important to stress that our article is summary of our practical experience and contains a lot of examples that could be very useful when developing (ICFs).The transcript will be available soon.
In this episode we are speaking with Georgi Kadrev, the CEO of Kelvin Health, about the impact and the future of artificial intelligence (AI) in medical diagnostics. We also discuss some of the challenges that medical diagnostics startups face when trying to bring their products to the market and what could the regulators do to support them. Georgi also provides insights on raising funding for medical diagnostics startups in Europe.The script for this episode is available here: https://solutionsop.co.uk/2025/09/03/ai-and-the-future-of-medical-diagnostics-conversation-with-georgi-kadrev/
This latest episode is an overview of the latest ICH GCP E6 (R3) changes and how they will affect clinical trials. This new guidance was released in Jan 2025 to provide further clarification on risk assessment and new technologies used in clinical research.
Our guest in this episode is the American entrepreneur, Charles Theuer, who has a long career in clinical research and drug development. He shares with us his analysis on the current trends and the future of oncology drug development. In this episode you can learn why there are less cancer clinical trials during the last years and what are the promising therapeutic classes.Charles has written 2 books which we also discuss in this episode. One of them, Unnecessary Expense, covers important topics in drug development and the importance of self-management of clinical trials which could be of interest for all small companies but also for industry experts.His books are available on Amazon below:Unnecessary Expense: An Antidote for the Billion Dollar Drug Problem - https://www.amazon.co.uk/Unnecessary-Expense-Antidote-Billion-Problem-ebook/dp/B09C2JNJ89Medal Count- https://www.amazon.co.uk/Medal-Count-Fate-Nations-Olympics-ebook/dp/B0F3617YFK?ref_=ast_author_dpYou can read the transcript here: https://solutionsop.co.uk/2025/07/25/latest-trends-and-the-future-of-cancer-research-in-conversation-with-charles-theuer/
Our guest in this episode of the podcast is Tommaso Prosdocimi, the Clinical Operations Manager of Iperboreal Pharma. Iperboreal Pharma is a small company developing new peritoneal dialysis products. We are discussing the necessity of having more treatment options of patients who need dialysis and also the unique challenges that small companies face in developing such products. Our conversation ends with some recommendations for regulators willing to support the development of dialysis products.You can read the script of our interview: https://solutionsop.co.uk/2025/07/11/the-reality-of-developing-dialysis-products-conversation-with-tommaso-prosdocimi/
Our latest episode is conversation with our Senior Clinical Data Quality Manager, Lydia Ainsworth, in which we discuss clinical research as a career choice and we give advice to graduates who are interested to work in the field. We cover topics like how to gain experience in clinical research, what universities can do to increase awareness in clinical research as career, if you need degree in biology to work in clinical research, some CV creation tips and many others.You can read the transcript of the interview at our website here.
This episode provides overview of the new clinical trials regulations in the UK which was signed into a law in April 2025. It highlights the main changes of the regulations and provides some background information what triggered these changes.
This episode is dedicated to the benefits of self-managed clinical trials for pharma startups. It discusses some of the complex issues that startups face with fully outsourcing clinical trials to clinical research organisations. It also covers what could companies do instead of fully outsourcing clinical trials and how this could help them in a long run.
This episode discusses the challenges of patients involvement in clinical trials design and documents review. While patients' contribution to clinical research is often important is some cases it could be very limited. On the other hand there is a growing reliance from the regulatory agencies on patients' involvement to review informed consents which brings additional complications.
This episode covers the reasons for red tape in the pharma industry and how to improve the interactions between the pharma industry and the regulators. The answer to the question who is responsible for the increasing red tape in the drug development is not simple but both the regulators and the pharma industry have to admit their contribution.
loading
Comments 
loading